The Effect of S-Allyl L-Cysteine on Retinal Ischemia: The Contributions of MCP-1 and PKM2 in the Underlying Medicinal Properties

Int J Mol Sci. 2024 Jan 22;25(2):1349. doi: 10.3390/ijms25021349.

Abstract

Retinal ischemia plays a vital role in vision-threatening retinal ischemic disorders, such as diabetic retinopathy, age-related macular degeneration, glaucoma, etc. The aim of this study was to investigate the effects of S-allyl L-cysteine (SAC) and its associated therapeutic mechanism. Oxidative stress was induced by administration of 500 μM H2O2 for 24 h; SAC demonstrated a dose-dependent neuroprotective effect with significant cell viability effects at 100 μM, and it concurrently downregulated angiogenesis factor PKM2 and inflammatory biomarker MCP-1. In a Wistar rat model of high intraocular pressure (HIOP)-induced retinal ischemia and reperfusion (I/R), post-administration of 100 μM SAC counteracted the ischemic-associated reduction of ERG b-wave amplitude and fluorogold-labeled RGC reduction. This study supports that SAC could protect against retinal ischemia through its anti-oxidative, anti-angiogenic, anti-inflammatory, and neuroprotective properties.

Keywords: S-allyl L-cysteine; hydrogen peroxide; monocyte chemoattractant protein-1; oxidative stress; pyruvate kinase M2; retinal ganglion cell; retinal ischemia; retinal pigment epithelium.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Cysteine / pharmacology
  • Cysteine / therapeutic use
  • Glaucoma* / drug therapy
  • Hydrogen Peroxide / therapeutic use
  • Ischemia / drug therapy
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Rats
  • Rats, Wistar
  • Reperfusion Injury* / drug therapy
  • Retinal Diseases* / drug therapy

Substances

  • S-allylcysteine
  • Cysteine
  • Hydrogen Peroxide
  • Neuroprotective Agents
  • Anti-Inflammatory Agents

Grants and funding

This research received no external funding.